具有新型ABL激酶抑制剂的优势意马替尼抗药性
Neil P Shah1, Chris Tran, Francis Y Lee
1Division of Hematology and Oncology, Department of Medicine, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Science (New York, N.Y.)
|July 17, 2004
概括
一种新药,BMS-354825,通过克服意马替尼抗性来治疗慢性髓性白血病 (CML) 是有前途的. 这种向治疗对抗抗性BCR-ABL突变是有效的,为改善患者结果提供了希望.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 慢性髓性白血病 (CML) 中的意马替尼抗性主要是由BCR-ABL激酶域点突变驱动的.
- 这些突变改变了药物结合,导致CML患者的治疗失败.
- 了解耐药机制对于开发下一代疗法至关重要.
研究的目的:
- 评估BMS-354825新型ABL激酶抑制剂对CML中对伊马替尼布耐药BCR-ABL突变的疗效.
- 在BCR-ABL驱动型白血病的临床前模型中评估BMS-354825的治疗潜力.
主要方法:
- 利用晶体学研究来预测抑制剂与耐药突变物结合.
- 在体外测试了BMS-354825对15种耐伊马替尼布的BCR-ABL突变体的活性.
- 评估了BMS-354825在BCR-ABL驱动疾病的小鼠模型和来自患者的骨髓原生细胞中的疗效.
主要成果:
- BMS-354825对15种对伊马替尼布耐药的BCR-ABL突变体中的14种表现出保留活性.
- 抑制剂显著延长了小鼠患有BCR-ABL驱动型白血病的存活时间.
- BMS-354825抑制了对伊马替尼布敏感和对伊马替尼布耐药的CML原始细胞的增殖.
结论:
- BMS-354825是一种强大的第二代ABL激酶抑制剂,对广泛的BCR-ABL突变有效,包括那些赋予意马替尼抗性的突变.
- 对抗性机制的分子洞察力可以有效指导优越的向癌症治疗的开发.
- BMS-354825对已经对伊马替尼布产生耐药性的CML患者显示出显著的治疗潜力.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...